Photosensitisation Facilitates Cross-priming of Adjuvant-free Protein Vaccines and Stimulation of Tumour-suppressing CD8 T Cells
Overview
Authors
Affiliations
Cancer vaccines aim to induce CD8 T cells infiltrating the tumour. For protein-based vaccines, the main biological barrier to overcome is the default MHC class-II-pathway, with activation of CD4 T cells rather than CD8 T cells. The latter requires antigens to access the cytosol and MHC class I antigen presentation. We applied photosensitiser and light to trigger disruption of antigen-containing endosomes and thereby MHC class I cross-presentation of a model cancer vaccine. This "photochemical internalisation" resulted in activation, proliferation, and IFN-γ production of cytotoxic CD8 T cells, which suppressed tumour growth by infiltrating CD8 T cells and caspase-3-dependent apoptosis. The process was independent of MHC class II, MyD88, and TLR4 signalling, but dependent on trypsin- and caspase-like proteasome activity and partly also on chloroquine. This novel method of vaccination may find applications in cancer immunotherapy where the activation of CD8 T cells is important.
Engineering customized nanovaccines for enhanced cancer immunotherapy.
Guo J, Liu C, Qi Z, Qiu T, Zhang J, Yang H Bioact Mater. 2024; 36:330-357.
PMID: 38496036 PMC: 10940734. DOI: 10.1016/j.bioactmat.2024.02.028.
Utilization of Stimuli-Responsive Biomaterials in the Formulation of Cancer Vaccines.
Singh A, Malviya R, Prajapati B, Singh S, Goyal P J Funct Biomater. 2023; 14(5).
PMID: 37233357 PMC: 10219237. DOI: 10.3390/jfb14050247.
Enhancement of Immune Responses Elicited by Nanovaccines through a Cross-Presentation Pathway.
Kim C, Lee J, Ju D, Kim S, Yun C, Cho C Tissue Eng Regen Med. 2023; 20(3):355-370.
PMID: 36884197 PMC: 9994410. DOI: 10.1007/s13770-023-00527-y.
Waeckerle-Men Y, Kotkowska Z, Bono G, Duda A, Kolm I, Varypataki E Front Immunol. 2022; 13:815609.
PMID: 35173729 PMC: 8841863. DOI: 10.3389/fimmu.2022.815609.
Otterhaug T, Janetzki S, Welters M, Hakerud M, Nedberg A, Edwards V Front Immunol. 2021; 11:576756.
PMID: 33488576 PMC: 7819858. DOI: 10.3389/fimmu.2020.576756.